These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 33287230)
21. Mesenchymal stem/stromal cell therapy for pulmonary arterial hypertension: Comprehensive review of preclinical studies. Fukumitsu M; Suzuki K J Cardiol; 2019 Oct; 74(4):304-312. PubMed ID: 31109735 [TBL] [Abstract][Full Text] [Related]
22. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405 [No Abstract] [Full Text] [Related]
23. Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension. Hudson J; Farkas L Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829978 [TBL] [Abstract][Full Text] [Related]
24. Current and emerging therapeutic approaches to pulmonary hypertension. Bisserier M; Pradhan N; Hadri L Rev Cardiovasc Med; 2020 Jun; 21(2):163-179. PubMed ID: 32706206 [TBL] [Abstract][Full Text] [Related]
25. Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Meloche J; Lampron MC; Nadeau V; Maltais M; Potus F; Lambert C; Tremblay E; Vitry G; Breuils-Bonnet S; Boucherat O; Charbonneau E; Provencher S; Paulin R; Bonnet S Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1513-1523. PubMed ID: 28473439 [TBL] [Abstract][Full Text] [Related]
26. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. McLendon JM; Joshi SR; Sparks J; Matar M; Fewell JG; Abe K; Oka M; McMurtry IF; Gerthoffer WT J Control Release; 2015 Jul; 210():67-75. PubMed ID: 25979327 [TBL] [Abstract][Full Text] [Related]
27. Noncoding RNAs in Pulmonary Arterial Hypertension: Current Knowledge and Translational Perspectives. Bernardi N; Bianconi E; Vecchi A; Ameri P Heart Fail Clin; 2023 Jan; 19(1):137-152. PubMed ID: 36435569 [TBL] [Abstract][Full Text] [Related]
28. Adipose-derived mesenchymal stromal cells improve hemodynamic function in pulmonary arterial hypertension: identification of microRNAs implicated in modulating endothelial function. Wang P; Zhang C; Li J; Luo L; Zhang S; Dong F; Tang Z; Ni S Cytotherapy; 2019 Apr; 21(4):416-427. PubMed ID: 30904330 [TBL] [Abstract][Full Text] [Related]
29. Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension. Reyes-Palomares A; Gu M; Grubert F; Berest I; Sa S; Kasowski M; Arnold C; Shuai M; Srivas R; Miao S; Li D; Snyder MP; Rabinovitch M; Zaugg JB Nat Commun; 2020 Apr; 11(1):1673. PubMed ID: 32245974 [TBL] [Abstract][Full Text] [Related]
31. NSD2 silencing alleviates pulmonary arterial hypertension by inhibiting trehalose metabolism and autophagy. Zhou XL; Liu ZB; Zhu RR; Huang H; Xu QR; Xu H; Zeng L; Li YY; Huang CH; Wu QC; Liu JC Clin Sci (Lond); 2019 May; 133(9):1085-1096. PubMed ID: 31040165 [TBL] [Abstract][Full Text] [Related]
32. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances. Mercurio V; Cuomo A; Naranjo M; Hassoun PM Compr Physiol; 2021 Apr; 11(2):1805-1829. PubMed ID: 33792903 [TBL] [Abstract][Full Text] [Related]
33. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906 [TBL] [Abstract][Full Text] [Related]
34. Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension. Gubrij IB; Pangle AK; Pang L; Johnson LG PLoS One; 2016; 11(1):e0147827. PubMed ID: 26815432 [TBL] [Abstract][Full Text] [Related]
35. RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword. Turton HA; Thompson AAR; Farkas L Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354189 [TBL] [Abstract][Full Text] [Related]
36. Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension. Fazal S; Bisserier M; Hadri L Cells; 2021 Mar; 10(3):. PubMed ID: 33805595 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway. Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452 [TBL] [Abstract][Full Text] [Related]
38. 2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. Huang WC; Hsu CH; Sung SH; Ho WJ; Chu CY; Chang CP; Chiu YW; Wu CH; Chang WT; Lin L; Lin SL; Cheng CC; Wu YJ; Wu SH; Hsieh TY; Hsu HH; Fu M; Dai ZK; Kuo PH; Hwang JJ; Cheng SM; J Formos Med Assoc; 2019 Dec; 118(12):1584-1609. PubMed ID: 30926248 [TBL] [Abstract][Full Text] [Related]
39. LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARĪ³ Activation. Calvier L; Boucher P; Herz J; Hansmann G Circ Res; 2019 Jun; 124(12):1778-1785. PubMed ID: 31023188 [TBL] [Abstract][Full Text] [Related]